BioInvent Banks $116m As NHL Drug Nears Phase III
Swedish Biotech Attracting International Investors
Executive Summary
Following positive interim results from a Phase I/IIa trial of BI-1206 in combination with Roche's Rituxan, BioInvent has raised a significant sum to push the non-Hodgkin's lymphoma drug towards late-stage development.